Chromocell to Present at Sidoti Virtual Investor Conference March 13-14
11 3월 2024 - 10:00PM
Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”),
(NYSE American: CHRO), a pioneer in the development of non-opioid
pain treatment therapeutics, today announced Frank Knuettel, CEO,
will present and host one-on-one meetings with investors at the
Sidoti March Virtual Investor Conference, taking place on March
13-14, 2024.
Chromocell’s presentation will begin March 13 at 2:30-3:00 PM in
Track 3 and can be accessed live here:
https://sidoti.zoom.us/webinar/register/WN_D2qavsKxRjOQeRlFjjLw7A.
The Company will also host virtual one-on-ones with investors on
Wednesday and Thursday, March 13-14, 2024. To register for the
presentation or one-on-ones, visit www.sidoti.com/events.
Registration is free and you don't need to be a Sidoti client.
About Sidoti Events, LLC (“Events”) and Sidoti &
Company, LLC (“Sidoti”)
In 2023, Sidoti & Company, LLC, Sidoti & Company,
LLC (www.sidoti.com) formed a sister company, Sidoti Events,
LLC in order to focus exclusively on its rapidly growing conference
business and to more directly serve the needs of presenters and
attendees. The relationship allows Events to draw on the
nearly 25 years of experience Sidoti has as a premier provider of
independent securities research focused specifically on small and
microcap companies and the institutions that invest in their
securities, with most of its coverage in the $200 million-$5
billion market cap range. Sidoti’s coverage universe comprises
approximately 160 equities, of which 40 percent participate in the
firm's rapidly growing Company Sponsored Research ("CSR") program.
Events is a leading provider of corporate access through the
eight investor conferences it hosts each year. By virtue of its
direct ties to Sidoti, Events benefits from Sidoti’s small- and
microcap-focused nationwide sales force, which has connections with
approximately 1,500 institutional relationships in North
America. This enables Events to provide multiple forums for
meaningful interaction for small and microcap issuers and investors
specifically interested in companies in the sector.
About Chromocell Therapeutics
Corp.
Chromocell Therapeutics Corporation is a
clinical-stage biotechnology company focused on developing and
commercializing novel, non-opioid, non-addictive, therapeutics to
alleviate pain and other associated medical conditions. The
Company’s initial clinical focus is to selectively target the
sodium ion-channel known as NaV1.7 for the treatment of various
types of chronic neuropathic pain and eye pain. The Company’s
portfolio also includes pre-clinical work on other sodium channel
receptor subtypes and the Company intends to explore these and
other compounds for the treatment of additional pain indications.
For company updates and to learn more about Chromocell,
visit www.chromocell.com or follow us on social
media.
Forward-Looking Statements
This press release contains forward-looking
statements regarding the Company’s current expectations. These
forward-looking statements include, without limitation, references
to the Company’s expectations regarding the closing of the public
offering and its anticipated use of net proceeds from the offering.
These statements are not guarantees of future performance and are
subject to certain risks, uncertainties and assumptions that are
difficult to predict. Factors that could cause actual results to
differ include, but are not limited to, risks and uncertainties
related to the satisfaction of customary closing conditions related
to the public offering, or factors that result in changes to the
Company’s anticipated use of proceeds. These and other risks and
uncertainties are described more fully in the section captioned
“Risk Factors” in the Company’s Registration Statement on Form S-1
related to the public offering (SEC File No. 333-269188).
Forward-looking statements contained in this announcement are made
as of this date, and the Company undertakes no duty to update such
information except as required under applicable law.
Chromocell Media and Investor Inquiries:
LR Advisors
LLC. Jason
Assad 678-570-6791 Jason@Chromocell.com
Chromocell Therapeutics (AMEX:CHRO)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Chromocell Therapeutics (AMEX:CHRO)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024